Table 1 Baseline Characteristics
From: Outcomes of Cardiac Resynchronization Therapy in Patients with Hypothyroidism and Heart Failure
Variable | All (n = 1316) | Euthyroidism (n = 966) | Hypothyroidism (n = 350) | P Value |
|---|---|---|---|---|
Age, y | 69.8 ± 12.2 | 69.3 ± 12.4 | 71.2 ± 11.2 | 0.01 |
Female | 289 (22.0) | 184 (19.0) | 105 (30.0) | < 0.001 |
CRT-D | 1181 (89.7) | 867 (89.7) | 314 (90.0) | 0.87 |
Primary prevention | 979 (82.9) | 749 (86.5) | 230 (73.0) | < 0.001 |
Hypertension | 539 (41.0) | 398 (41.2) | 141 (40.4) | 0.81 |
Diabetes mellitus | 398 (30.2) | 297 (30.7) | 101 (28.9) | 0.54 |
Chronic kidney disease | 357 (27.1) | 248 (25.7) | 109 (31.2) | 0.04 |
Hyperlipidemia | 600 (45.7) | 442 (45.7) | 158 (45.4) | 0.92 |
Atrial fibrillation history | 599 (44.5) | 430 (44.5) | 169 (48.4) | 0.20 |
ICM | 632 (48.0) | 462 (47.8) | 170 (48.7) | 0.77 |
LBBB | 644 (40.1) | 491 (52.2) | 153 (44.5) | 0.02 |
QRS duration, ms | 170.2 ± 28.5 | 169.5 ± 28.2 | 172.1 ± 29.4 | 0.16 |
NYHA functional class, 1–4 | 2.8 ± 0.6 | 2.8 ± 0.6 | 2.9 ± 0.5 | 0.64 |
3–4 | 892 | 644 (69.7) | 248 (73.6) | |
2 | 349 | 264 (28.6) | 85 (25.2) | |
1 | 20 | 16 (1.7) | 4 (1.2) | |
LVEF, % | 24.3 ± 6.5 | 24.2 ± 6.6 | 24.4 ± 6.6 | 0.62 |
TRT | 254 (19.3) | 0 (0) | 254 (72.9) | < 0.001 |
Amiodarone | 232 (17.6) | 135 (14.0) | 97 (27.9) | < 0.001 |
Statin | 705 (53.6) | 529 (54.7) | 176 (50.4) | 0.17 |
Digoxin | 539 (41.0) | 391 (40.4) | 148 (42.4) | 0.52 |
β-blocker | 1156 (87.8) | 853 (88.2) | 303 (86.8) | 0.50 |
ACEI/ARB | 1054 (80.1) | 781 (80.8) | 273 (78.2) | 0.31 |
Aldactone | 391 (29.7) | 288 (29.8) | 103 (29.5) | 0.93 |
Furosemide | 886 (67.3) | 640 (66.2) | 246 (70.5) | 0.14 |